Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEALTIME TREATMENT WITH INSULIN ANALOG IMPROVES POSTPRANDIAL HYPERGLYCEMIA AND HYPOGLYCEMIA IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS
Autore:
ANDERSON JH; BRUNELLE RL; KEOHANE P; KOIVISTO VA; TRAUTMANN ME; VIGNATI L; DIMARCHI R;
Indirizzi:
ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,DIV DIABET CARE & ENDOCRINOL INDIANAPOLIS IN 46285 UNIV HELSINKI HOSP,DEPT MED HELSINKI FINLAND
Titolo Testata:
Archives of internal medicine
fascicolo: 11, volume: 157, anno: 1997,
pagine: 1249 - 1255
SICI:
0003-9926(1997)157:11<1249:MTWIAI>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRO(B29)>-HUMAN INSULIN; STATISTICAL-ANALYSIS; DENSITY LIPOPROTEIN; INJECTION; NIDDM; CHOLESTEROL; )LYS(B28); DISEASE; DESIGN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
J.H. Anderson et al., "MEALTIME TREATMENT WITH INSULIN ANALOG IMPROVES POSTPRANDIAL HYPERGLYCEMIA AND HYPOGLYCEMIA IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS", Archives of internal medicine, 157(11), 1997, pp. 1249-1255

Abstract

Background: Insulin lispro is an insulin analog that was recently developed particularly for a mealtime therapy. It has a fast absorption rate and short duration of action. The efficacy of insulin lispro in the clinical therapy of patients with non-insulin-dependent diabetes mellitus (NIDDM) has not been tested. Objectives: To compare insulin lispro and human regular insulin in the mealtime treatment of patients with NIDDM. Methods: A 6-month, randomized, multinational (16 countries),multicenter (80 sites) clinical trial with an open-label, crossover design was performed in 722 patients with NIDDM. Insulin lispro was injected immediately before and human regular insulin 30 to 45 minutes before the meal. Results: Throughout the study, the postprandial rise inserum glucose levels was significantly lower during insulin lispro than human regular insulin treatment. At end point the rise (mean SEM) in serum glucose levels was 30% lower at 1 hour (2.6+/-0.1 mmol/L [46.8/-1.8 mg/ dL] for lispro vs 3.7+/-0.1 mmol/L [66.6+/-1.8 mg/dL] for human regular insulin) and 53% lower 2 hours after the test meal (1.4+/-0.1 mmol/L [25.2+/-1.8 mg/dL] for lispro vs 3.0+/-0.1 mmol/L [54.0+/-1.8 mg/dL] for human regular insulin) with insulin lispro compared with human regular insulin therapy (P<.001 for both intervals). During insulin lispro therapy the rate of hypoglycemia overall (P=.01) and overnight (P<.001) was lower and the number of asymptomatic hypoglycemic episodes was smaller (P=.03) than during human regular insulin therapy. Associated with a similar 13% increase (P<.001) in the total daily insulin dose, the glycosylated hemoglobin level decreased (P<.001) equally in both treatment groups. Serum lipid and lipoprotein levels remained unchanged. There were no differences in the adverse events between the 2 treatment groups. Conclusions: Compared with human regular insulin therapy, mealtime therapy with insulin lispro reduced postprandial hyperglycemia and may decrease the rate of mild hypoglycemic episodes in patients with NIDDM.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 16:04:14